Journal
CLINICAL SCIENCE
Volume 135, Issue 14, Pages 1707-1726Publisher
PORTLAND PRESS LTD
DOI: 10.1042/CS20210100
Keywords
-
Categories
Funding
- National Natural Science Foundation [81800599, 81873599, 81770690, 82070701, 81800638]
- Natural Science Foundation of Jiangsu Province [BK20180145]
- Nanjing City Key Medical Research Project [ZKX18039]
Ask authors/readers for more resources
The study found that FG4592 may play a role in the transition from AKI to CKD by alleviating kidney fibrosis and enhancing renal vascular regeneration through activating the HIF-1α/VEGFA/VEGFR1 signaling pathway and driving SOD2 expression. Moreover, FG4592 can also improve metabolic disorders in the kidneys.
Acute kidney injury (AKI) is a known risk factor for the development of chronic kidney disease (CKD), with no satisfactory strategy to prevent the progression of AKI to CKD. Damage to the renal vascular system and subsequent hypoxia are common contributors to both AKI and CKD. Hypoxia-inducible factor (HIF) is reported to protect the kidney from acute ischemic damage and a novel HIF stabilizer, FG4592 (Roxadustat), has become available in the clinic as an anti-anemia drug. However, the role of FG4592 in the AKI-to-CKD transition remains elusive. In the present study, we investigated the role of FG4592 in the AKI-to-CKD transition induced by unilateral kidney ischemia-reperfusion (UIR). The results showed that FG4592, given to mice 3 days after UIR, markedly alleviated kidney fibrosis and enhanced renal vascular regeneration, possibly via activating the HIF-1 alpha/vascular endothelial growth factor A (VEGFA)/VEGF receptor 1 (VEGFR1) signaling pathway and driving the expression of the endogenous antioxidant superoxide dismutase 2 (SOD2). In accordance with the improved renal vascular regeneration and redox balance, the metabolic disorders of the UIR mice kidneys were also attenuated by treatment with FG4592. However, the inflammatory response in the UIR kidneys was not affected significantly by FG4592. Importantly, in the kidneys of CKD patients, we also observed enhanced HIF-1 alpha expression which was positively correlated with the renal levels of VEGFA and SOD2. Together, these findings demonstrated the therapeutic effect of the anti-anemia drug FG4592 in preventing the AKI-to-CKD transition related to ischemia and the redox imbalance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available